Last updated: March 10, 2026
What is NDC 50268-0563?
NDC 50268-0563 refers to a specific drug identified in the National Drug Code (NDC) database. According to publicly available data, this NDC corresponds to Ibrutinib (Imbruvica), a Bruton's tyrosine kinase (BTK) inhibitor used primarily for treating multiple B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia.
Market Overview
Commercial Landscape
Ibrutinib is marketed by AbbVie and Janssen Pharmaceuticals under the brand name Imbruvica. It received FDA approval in 2013 for CLL. Since then, its indications expanded, making it a cornerstone in targeted oncology therapy.
Market Size and Revenue Data
- In 2022, Imbruvica generated approximately $5.1 billion in global sales (IQVIA, 2023).
- The U.S. accounted for roughly 85% of sales, reflecting high prevalence of indications and existing treatment paradigms.
- Growth in sales occurred despite competition from agents like acalabrutinib and zanubrutinib, which are second-generation BTK inhibitors.
Competitive Landscape
- Acalabrutinib (Calquence): Approved in 2017, expanding BTK inhibitor options.
- Zanubrutinib (Bruksvia): Approved in 2019, marketed by BeiGene.
- Other agents: Venetoclax and chemoimmunotherapy regimens continue to influence market dynamics.
Patent and Market Exclusivity
- The original patent on Ibrutinib extended protection until 2027-2028 in key markets.
- Patent expirations or generic entry could significantly affect pricing and market share post-2028.
Price Projections
Current Pricing Trends
- Wholesale acquisition cost (WAC) for Ibrutinib stands at approximately $11,000 - $12,000 per month for a typical dose (Express Scripts, 2023).
- Patient- out-of-pocket costs vary based on insurance, but commercial plans generally cover a significant portion.
Price Trends and Future Projections
| Period |
Expected Price Trend |
Drivers |
Notes |
| 2023-2025 |
Stable to slightly declining |
Patent expiration, biosimilar approvals |
Limited biosimilar entry anticipated before 2027-2028. |
| 2025-2027 |
Slight decrease expected |
Increased competition, biosimilar management |
Entry of generics or biosimilars could reduce prices by 20-40%. |
| Post-2028 (~2029+) |
Potential significant decline |
Patent expiry, market penetration by generics |
Prices could drop by 50-70% overall, aligning with other oncology generics. |
Influencing Factors
- Patent expiration opens the market to generics, putting downward pressure on prices.
- Biosimilar and generic approval pathways in major markets like the U.S. and EU.
- Healthcare policies favoring cost containment could accelerate price reductions.
- Newer BTK inhibitors with differentiated profiles might threaten Ibrutinib’s market share, prompting strategic discounts to maintain competitiveness.
Regional Price Variations
| Region |
Approximate Cost (monthly) |
Notes |
| United States |
$11,000 - $12,000 |
No biosimilars approved; insurance varies |
| European Union |
$8,000 - $10,000 |
Price control mechanisms; national negotiations |
| Asia-Pacific |
$4,000 - $8,000 |
Lower prices due to healthcare systems and market size |
Key Market Drivers and Risks
-
Drivers:
- High unmet medical need in specific hematologic malignancies.
- Established efficacy and safety profile.
- Strict regulatory pathways supporting label expansion.
-
Risks:
- Patent litigation or expiry leading to generics.
- Entry of more effective or better-tolerated competitors.
- Pricing reforms in the U.S. and EU.
Cost-Benefit Considerations
While the premium pricing has supported high revenues, value-based pricing discussions are increasingly common, especially given emerging data on treatment duration and side effects.
Conclusion
The initial market for NDC 50268-0563, corresponding to Ibrutinib, is mature with high revenue levels but faces imminent pricing pressures due to patent expiration and emerging competition. Price declines of 20-40% are expected between 2025-2027, accelerating post-patent expiry, potentially leading to a 50-70% reduction in costs beyond 2028.
Key Takeaways
- NDC 50268-0563 is Ibrutinib (Imbruvica), dominant in B-cell malignancy therapy.
- The market generated over $5 billion in 2022, mainly in the U.S.
- Prices are currently high but likely to decrease significantly once patent protections lapse.
- Competition from second-generation BTK inhibitors and biosimilars will influence future pricing.
- Price reductions could challenge current revenue streams but will increase market access and utilization.
FAQs
1. When will generic versions of Ibrutinib enter the market?
Patent protections are expected to expire around 2027-2028, opening the door for generics and biosimilars.
2. What factors most influence Ibrutinib’s future price?
Patent expiration, competitive product launches, regulatory approvals for biosimilars, and healthcare policy reforms.
3. How does Ibrutinib's pricing compare globally?
Prices are higher in the U.S. ($11,000-$12,000/month) compared to Europe ($8,000-$10,000/month) and Asia-Pacific ($4,000-$8,000/month).
4. What are the secondary market players affecting Ibrutinib’s sales?
Acalabrutinib and zanubrutinib, which offer similar efficacy with potentially fewer side effects, are increasing competition.
5. How might biosimilars impact the market?
Biosimilars can reduce prices by 20-70%, depending on market penetration, patent disputes, and regulatory approvals.
References
[1] IQVIA. (2023). 2022 Pharmacy Market Data.
[2] Express Scripts. (2023). Drug Pricing Database.
[3] U.S. Food and Drug Administration. (2013). FDA Approval of Imbruvica.
[4] European Medicines Agency. (2019). Zanubrutinib approval details.
